Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
General Aim: To assess the efficacy and safety of BGC20-0134 in patients with RRMS treated for 24 weeks in in the double-blind period and for a further 24 weeks in the open-label period Primary Endpoint: Cumulative number of new gadolinium-enhanced (GdE) T1 weighted lesions developing while on treatment (specifically the sum of new GdE T1 lesions seen on MRI at weeks 12, 16, 20 and 24)
Inclusion criteria
- Relapsing-Remitting Multiple Sclerosis